Exact Mass: 566.2678
Exact Mass Matches: 566.2678
Found 500 metabolites which its exact mass value is equals to given mass value 566.2678
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Canescein
Canescein is isolated from Convallaria majalis. Convallaria majalis is banned by the FDA from food use in the US
Hordatine A
Alkaloid from barley (Hordeum vulgare). Hordatine A is found in barley and cereals and cereal products. Hordatine A is found in barley. Hordatine A is an alkaloid from barley (Hordeum vulgare
Mesoporphyrin IX
Mesoporphyrins are porphyrins with four methyl, two ethyl, and two propionic acid side chains attached to the pyrrole rings. There are fifteen isomers of mesoporphyrin. Mesoporphyrin has anti-inflammatory action. Mesoporphyrin inhibits interferon-gamma and interleukin-6 production, which is closely related to the suppression of prostaglandin E2 generation by interfering cyclooxygenase 1 and 2 enzyme activities suggesting that the inhibition of cytokine production is one of the anti-inflammatory mechanisms of mesoporphyrin. (PMID: 10446754). Mesoporphyrins are porphyrins with four methyl, two ethyl, and two propionic acid side chains attached to the pyrrole rings. There are fifteen isomers of mesoporphyrin.
(4r,5s,6s,7r)-4,7-Dibenzyl-5,6-dihydroxy-1,3-bis[4-(hydroxymethyl)benzyl]-1,3-diazepan-2-one
PA(2:0/6 keto-PGF1alpha)
PA(2:0/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/6 keto-PGF1alpha), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(6 keto-PGF1alpha/2:0)
PA(6 keto-PGF1alpha/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/2:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/TXB2)
PA(2:0/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/TXB2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(TXB2/2:0)
PA(TXB2/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/2:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
(3S,5S,10S,13R,14S,17R)-5,14-dihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-3-[(2R,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde
(1R,2S,4S,5S,6R,7S,8S,9R,10S)-1-acetoxy-9-benzoyloxy-8-trans-cinnamoyloxy-2,4,6-trihydroxydihydro-beta-agarofuran
(3beta)-3-O-(sulfo)lup-20(29)-en-23,28-dioic acid|gypsophilin
3beta-(beta-D-glucopyranosyloxy)-19-carboxy-14beta-hydroxycard-20(22)-enolide
peroxysampsone A|rel-(1R,3S,7S,9S,11R,13S)-11-benzoyl-3-(1-hydroperoxy-1-methylethyl)-6,6,10,10-tetramethyl-13-(3-methylbut-2-en-1-yl)-4,5-dioxatetracyclo[9.3.1.1(9,13).0(1,7)]hexadecane-12,14,15-trione
(20S,22S,23S,24S,25S,26S)-5alpha-chloro-12alpha,22-23,26,24,25-triepoxy-12-ethoxy-6beta,17beta,26-trihydroxyergosta-2-en-1-one|12-O-ethyl-jaborosalactol 25|12-O-ethyljaborosalactol 25
Asn Tyr Arg Asp
Asn Tyr Asp Arg
Tyr Thr Gln Arg
3-[[6-[[1,4a-dimethyl-6-methylidene-5-[2-(5-oxo-2H-furan-4-yl)ethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalen-1-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-3-oxopropanoic acid
(8xi,11alpha,14xi,17alpha)-3-[(6-Deoxyhexopyranosyl)oxy]-5,11,14-trihydroxy-19-oxocard-20(22)-enolide
Origin: Plant, Cardanolides
3-[[6-[[1,4a-dimethyl-6-methylidene-5-[2-(5-oxo-2H-furan-4-yl)ethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalen-1-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-3-oxopropanoic acid_major
Ala Lys Trp Tyr
Ala Lys Tyr Trp
Ala Gln Trp Tyr
Ala Gln Tyr Trp
Ala Trp Lys Tyr
Ala Trp Gln Tyr
Ala Trp Tyr Lys
Ala Trp Tyr Gln
Ala Tyr Lys Trp
Ala Tyr Gln Trp
Ala Tyr Trp Lys
Ala Tyr Trp Gln
Asp Asn Arg Tyr
Asp Asn Tyr Arg
Asp Arg Asn Tyr
Asp Arg Tyr Asn
Asp Tyr Asn Arg
Asp Tyr Arg Asn
Glu Lys Gln Tyr
Glu Lys Tyr Gln
Glu Gln Lys Tyr
Glu Gln Tyr Lys
Glu Tyr Lys Gln
Glu Tyr Gln Lys
Phe His Thr Tyr
Phe His Tyr Thr
Phe Lys Ser Trp
Phe Lys Trp Ser
Phe Met Asn Arg
Phe Met Arg Asn
Phe Asn Met Arg
Phe Asn Arg Met
Phe Asn Thr Trp
Phe Asn Trp Thr
Phe Gln Ser Trp
Phe Gln Trp Ser
Phe Arg Met Asn
Phe Arg Asn Met
Phe Ser Lys Trp
Phe Ser Gln Trp
Phe Ser Trp Lys
Phe Ser Trp Gln
Phe Thr His Tyr
Phe Thr Asn Trp
Phe Thr Trp Asn
Phe Thr Tyr His
Phe Trp Lys Ser
Phe Trp Asn Thr
Phe Trp Gln Ser
Phe Trp Ser Lys
Phe Trp Ser Gln
Phe Trp Thr Asn
Phe Tyr His Thr
Phe Tyr Thr His
His Phe Thr Tyr
His Phe Tyr Thr
His His His His
His Lys Pro Trp
His Lys Trp Pro
His Pro Lys Trp
His Pro Gln Trp
His Pro Trp Lys
His Pro Trp Gln
His Gln Pro Trp
His Gln Trp Pro
His Thr Phe Tyr
His Thr Tyr Phe
His Trp Lys Pro
His Trp Pro Lys
His Trp Pro Gln
His Trp Gln Pro
His Tyr Phe Thr
His Tyr Thr Phe
Lys Ala Trp Tyr
Lys Ala Tyr Trp
Lys Glu Gln Tyr
Lys Glu Tyr Gln
Lys Phe Ser Trp
Lys Phe Trp Ser
Lys His Pro Trp
Lys His Trp Pro
Lys Pro His Trp
Lys Pro Trp His
Lys Gln Glu Tyr
Lys Gln Tyr Glu
Lys Ser Phe Trp
Lys Ser Trp Phe
Lys Trp Ala Tyr
Lys Trp Phe Ser
Lys Trp His Pro
Lys Trp Pro His
Lys Trp Ser Phe
Lys Trp Tyr Ala
Lys Tyr Ala Trp
Lys Tyr Glu Gln
Lys Tyr Gln Glu
Lys Tyr Trp Ala
Met Phe Asn Arg
Met Phe Arg Asn
Met Asn Phe Arg
Met Asn Arg Phe
Met Arg Phe Asn
Met Arg Asn Phe
Asn Asp Arg Tyr
Asn Asp Tyr Arg
Asn Phe Met Arg
Asn Phe Arg Met
Asn Phe Thr Trp
Asn Phe Trp Thr
Asn Met Phe Arg
Asn Met Arg Phe
Asn Arg Asp Tyr
Asn Arg Phe Met
Asn Arg Met Phe
Asn Arg Tyr Asp
Asn Thr Phe Trp
Asn Thr Trp Phe
Asn Trp Phe Thr
Asn Trp Thr Phe
Pro His Lys Trp
Pro His Gln Trp
Pro His Trp Lys
Pro His Trp Gln
Pro Lys His Trp
Pro Lys Trp His
Pro Gln His Trp
Pro Gln Trp His
Pro Trp His Lys
Pro Trp His Gln
Pro Trp Lys His
Pro Trp Gln His
Gln Ala Trp Tyr
Gln Ala Tyr Trp
Gln Glu Lys Tyr
Gln Glu Tyr Lys
Gln Phe Ser Trp
Gln Phe Trp Ser
Gln His Pro Trp
Gln His Trp Pro
Gln Lys Glu Tyr
Gln Lys Tyr Glu
Gln Pro His Trp
Gln Pro Trp His
Gln Arg Thr Tyr
Gln Arg Tyr Thr
Gln Ser Phe Trp
Gln Ser Trp Phe
Gln Thr Arg Tyr
Gln Thr Tyr Arg
Gln Trp Ala Tyr
Gln Trp Phe Ser
Gln Trp His Pro
Gln Trp Pro His
Gln Trp Ser Phe
Gln Trp Tyr Ala
Gln Tyr Ala Trp
Gln Tyr Glu Lys
Gln Tyr Lys Glu
Gln Tyr Arg Thr
Gln Tyr Thr Arg
Gln Tyr Trp Ala
Arg Asp Asn Tyr
Arg Asp Tyr Asn
Arg Phe Met Asn
Arg Phe Asn Met
Arg Met Phe Asn
Arg Met Asn Phe
Arg Asn Asp Tyr
Arg Asn Phe Met
Arg Asn Met Phe
Arg Asn Tyr Asp
Arg Gln Thr Tyr
Arg Gln Tyr Thr
Arg Thr Gln Tyr
Arg Thr Tyr Gln
Arg Tyr Asp Asn
Arg Tyr Asn Asp
Arg Tyr Gln Thr
Arg Tyr Thr Gln
Ser Phe Lys Trp
Ser Phe Gln Trp
Ser Phe Trp Lys
Ser Phe Trp Gln
Ser Lys Phe Trp
Ser Lys Trp Phe
Ser Gln Phe Trp
Ser Gln Trp Phe
Ser Trp Phe Lys
Ser Trp Phe Gln
Ser Trp Lys Phe
Ser Trp Gln Phe
Thr Phe His Tyr
Thr Phe Asn Trp
Thr Phe Trp Asn
Thr Phe Tyr His
Thr His Phe Tyr
Thr His Tyr Phe
Thr Asn Phe Trp
Thr Asn Trp Phe
Thr Gln Arg Tyr
Thr Gln Tyr Arg
Thr Arg Gln Tyr
Thr Arg Tyr Gln
Thr Trp Phe Asn
Thr Trp Asn Phe
Thr Tyr Phe His
Thr Tyr His Phe
Thr Tyr Gln Arg
Thr Tyr Arg Gln
Trp Ala Lys Tyr
Trp Ala Gln Tyr
Trp Ala Tyr Lys
Trp Ala Tyr Gln
Trp Phe Lys Ser
Trp Phe Asn Thr
Trp Phe Gln Ser
Trp Phe Ser Lys
Trp Phe Ser Gln
Trp Phe Thr Asn
Trp His Lys Pro
Trp His Pro Lys
Trp His Pro Gln
Trp His Gln Pro
Trp Lys Ala Tyr
Trp Lys Phe Ser
Trp Lys His Pro
Trp Lys Pro His
Trp Lys Ser Phe
Trp Lys Tyr Ala
Trp Asn Phe Thr
Trp Asn Thr Phe
Trp Pro His Lys
Trp Pro His Gln
Trp Pro Lys His
Trp Pro Gln His
Trp Gln Ala Tyr
Trp Gln Phe Ser
Trp Gln His Pro
Trp Gln Pro His
Trp Gln Ser Phe
Trp Gln Tyr Ala
Trp Ser Phe Lys
Trp Ser Phe Gln
Trp Ser Lys Phe
Trp Ser Gln Phe
Trp Thr Phe Asn
Trp Thr Asn Phe
Trp Tyr Ala Lys
Trp Tyr Ala Gln
Trp Tyr Lys Ala
Trp Tyr Gln Ala
Tyr Ala Lys Trp
Tyr Ala Gln Trp
Tyr Ala Trp Lys
Tyr Ala Trp Gln
Tyr Asp Asn Arg
Tyr Asp Arg Asn
Tyr Glu Lys Gln
Tyr Glu Gln Lys
Tyr Phe His Thr
Tyr Phe Thr His
Tyr His Phe Thr
Tyr His Thr Phe
Tyr Lys Ala Trp
Tyr Lys Glu Gln
Tyr Lys Gln Glu
Tyr Lys Trp Ala
Tyr Asn Asp Arg
Tyr Asn Arg Asp
Tyr Gln Ala Trp
Tyr Gln Glu Lys
Tyr Gln Lys Glu
Tyr Gln Arg Thr
Tyr Gln Thr Arg
Tyr Gln Trp Ala
Tyr Arg Asp Asn
Tyr Arg Asn Asp
Tyr Arg Gln Thr
Tyr Arg Thr Gln
Tyr Thr Phe His
Tyr Thr His Phe
Tyr Thr Arg Gln
Tyr Trp Ala Lys
Tyr Trp Ala Gln
Tyr Trp Lys Ala
Tyr Trp Gln Ala
8H-7,10-Methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid, 5-(1,1-diMethylethyl)-1,1a,3,4,5,6,9,10,20,21,22,22a-dodecahydro-14-Methoxy-3,6-dioxo-, Methyl ester, (1aR,5S,8S,10R,18E,22aR)-
ethyl 3-(2-(((4-(ethoxy(imino)methyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate hydrochloride
Phenylmethyl 4,6-bis-O-(3-hydroxypropyl)-2,3-bis-O-(phenylmethyl)-alpha-D-glucopyranoside
(2R)-1-(1H-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol,(2R)-1-(3H-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol,dihydrochloride
3beta-[(6-Deoxy-alpha-L-mannopyranosyl)oxy]-5,11alpha,14-trihydroxy-19-oxo-5beta-card-20(22)-enolide
Protoporphyrinogen(2-)
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
3-[(21S,22S)-11,26-diethyl-4-hydroxy-16-[(1R)-1-hydroxyethyl]-12,17,21-trimethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
3-[(21S,22S)-11-ethyl-4-hydroxy-16-[(1R)-1-hydroxyethyl]-12,17,19,21,26-pentamethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
(4r,5s,6s,7r)-4,7-Dibenzyl-5,6-dihydroxy-1,3-bis[4-(hydroxymethyl)benzyl]-1,3-diazepan-2-one
A 1,3-diazepanone ring with two 4-(hydroxymethyl)benzyl groups as substituents at positions N-1 and N-4, two benzyl groups at C-4 and C-7, and two hydroxy groups at C-5 and C-6 respectively. D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
Cyclopropyl-[5-[[4-[[4-(2-methoxyphenyl)-1-piperazinyl]-oxomethyl]-1-piperidinyl]sulfonyl]-2-methyl-2,3-dihydroindol-1-yl]methanone
(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-2-carboxylatoethyl]sulfanyl}-5-hydroxyicosa-7,9,11,14-tetraenoate
N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(3-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-cyanobenzamide
1-(3-methoxyphenyl)-3-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3,3,3-trifluoropropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-methylbenzenesulfonamide
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-phenylmethanesulfonamide
1-(2-fluorophenyl)-3-[(4R,7R,8S)-5-[(2-fluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
3-[(21S,22S)-11,26-diethyl-4-hydroxy-16-(1-hydroxyethyl)-12,17,21-trimethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
S-[2-[3-[[(2R)-2-hydroxy-3,3-dimethyl-4-phosphonooxybutanoyl]amino]propanoylamino]ethyl] (Z)-tetradec-9-enethioate
[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
N-[4-(Diaminomethylideneamino)butyl]-5-[(Z)-3-[4-(diaminomethylideneamino)butylamino]-3-oxoprop-1-enyl]-7-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-1-benzofuran-3-carboxamide
S-tetradecanoyl-4-phosphopantetheine(2-)
An S-acyl-4-phosphopantetheine obtained by deprotonation of the phosphate OH groups of S-tetradecanoyl-4-phosphopantetheine; major species at pH 7.3.
leukotriene F4(2-)
A leukotriene anion obtained by deprotonation of the three carboxy groups and protonation of the glutamyl alpha-amino group of leukotriene F4; major species at pH 7.3.
({20-chloro-13,19,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-hexaen-9-yl}oxy)methanimidic acid
6-(furan-3-yl)-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl 2,3-dimethylbut-2-enoate
(1r,3as,3br,5as,7s,9as,9bs,11r,11as)-3a,5a,11-trihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-7-{[(2r,3r,4r,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde
(1z,4s,5r,14r,15s,16s,19z)-14,16-dihydroxy-15-methoxy-5,6,6,21,21-pentamethyl-3,7,18,23-tetraazaoctacyclo[16.13.0.0³,¹⁶.0⁴,⁷.0⁴,¹⁴.0⁸,¹³.0²²,³⁰.0²⁴,²⁹]hentriaconta-1(31),8,10,12,19,22(30),24,26,28-nonaene-2,17-dione
3-[5-(carboxymethyl)-9,14,20-triethyl-10,15,19-trimethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1³,⁶.1⁸,¹¹.1¹³,¹⁶]tetracosa-1,3,5,7,9,11(23),12,14,16,18(21),19-undecaen-4-yl]propanoic acid
4-[(1s,3s,5s,7r,9s,10r,12s,14s,15s,17r,18s,19r,22s,23r)-9,10,17,22-tetrahydroxy-7,14-bis(hydroxymethyl)-18-methyl-4,6,11-trioxahexacyclo[12.11.0.0³,¹².0⁵,¹⁰.0¹⁵,²³.0¹⁸,²²]pentacosan-19-yl]-5h-furan-2-one
(1r,3as,3br,5as,7s,9as,9bs,11r,11as)-3a,5a,11-trihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-7-{[(2s,3r,4r,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde
34,38-dimethyl-8,10,15,22,27,29-hexaoxa-34,38-diazaundecacyclo[19.11.3.3⁴,¹⁶.2³,¹⁷.0¹,²¹.0²,¹⁸.0⁴,¹⁶.0⁵,¹³.0⁷,¹¹.0²⁴,³².0²⁶,³⁰]tetraconta-5,7(11),12,19,24,26(30),31,36-octaene
(1r,2r,4r,9r,10r,13r,14s,15s,17r)-9-(furan-3-yl)-15-(2-methoxy-2-oxoethyl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadec-5-en-17-yl (2e)-2-methylbut-2-enoate
methyl (19s,20s)-14-ethenyl-9-ethyl-20-(3-methoxy-3-oxopropyl)-5,10,15,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1³,⁶.1⁸,¹¹.1¹³,¹⁶]tetracosa-1(21),2,4,6,8(23),9,11,13,15,17-decaene-4-carboxylate
(1r,3as,3br,5as,7s,9as,9bs,11ar)-7-{[(2r,3r,4r,5r)-5-[(1r)-1,2-dihydroxyethyl]-3,4-dihydroxyoxolan-2-yl]oxy}-3a,5a-dihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde
(1z,19z)-14,16-dihydroxy-15-methoxy-5,6,6,21,21-pentamethyl-3,7,18,23-tetraazaoctacyclo[16.13.0.0³,¹⁶.0⁴,⁷.0⁴,¹⁴.0⁸,¹³.0²²,³⁰.0²⁴,²⁹]hentriaconta-1(31),8,10,12,19,22(30),24,26,28-nonaene-2,17-dione
2-deacetoxy-7,9-dideacetyltaxinine j
{"Ingredient_id": "HBIN005493","Ingredient_name": "2-deacetoxy-7,9-dideacetyltaxinine j","Alias": "NA","Ingredient_formula": "C33H42O8","Ingredient_Smile": "CC1=C2C(C(C3(C(CC(C2(C)C)CC1OC(=O)C)C(=C)C(CC3O)OC(=O)C=CC4=CC=CC=C4)C)O)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4704","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5alpha-cinnamoyloxy-2alpha,13alpha-dihydroxy-9alpha,10beta-diacetoxy-4(20),11-taxadiene
{"Ingredient_id": "HBIN011411","Ingredient_name": "5alpha-cinnamoyloxy-2alpha,13alpha-dihydroxy-9alpha,10beta-diacetoxy-4(20),11-taxadiene","Alias": "5\u03b1-cinnamoyloxy-2\u03b1,13\u03b1-dihydroxy-9\u03b1,10\u03b2-diacetoxy-4(20),11-taxadiene","Ingredient_formula": "C33H42O8","Ingredient_Smile": "CC1=C2C(C(C3(CCC(C(=C)C3C(C(C2(C)C)CC1O)O)OC(=O)C=CC4=CC=CC=C4)C)OC(=O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "30788;3714","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
antialloside
{"Ingredient_id": "HBIN016302","Ingredient_name": "antialloside","Alias": "NA","Ingredient_formula": "C29H42O11","Ingredient_Smile": "CC1C(C(C(C(O1)OC2CCC3(C4CC(C5(C(CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)O)C=O)O)O)O","Ingredient_weight": "566.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1374","TCMSP_id": "NA","TCM_ID_id": "6743;21611","PubChem_id": "56841093","DrugBank_id": "NA"}
β-antiarin
{"Ingredient_id": "HBIN017975","Ingredient_name": "\u03b2-antiarin","Alias": "NA","Ingredient_formula": "C29H42O11","Ingredient_Smile": "CC1C(C(C(C(O1)OC2CCC3(C4CC(C5(C(CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)O)C=O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1377","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}